RETRACTED: Effect of metformin pretreatment on pregnancy outcome of in vitro matured oocytes retrieved from women with polycystic ovary syndrome

Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review

“…Thus, metformin could induce a follicular development similar to that observed in healthy women, minimizing hypoxic damage and cytoplasmatic/chromosomal disorders related to poor vascularization (252), as observed in CC-stimulated ovulatory cycles (29), and improving the oocyte and embryo quality. In this regard, an interesting study showed that a 15-d metformin pretreatment, at a dosage of 2000 mg/d, increased the high-quality embryos (37.8 vs. 24.3%), implantation (15.3 vs. 6.2%), and pregnancy (38.2 vs. 16.7%) rates in CC-resistant PCOS patients who underwent in vitro matured oocyte treatment, confirming a potential beneficial role of metformin on oocyte/embryo factors, even if an effect of endometrial receptivity cannot be excluded (254).…”

Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial

“…The role of metformin with respect to the improvement of embryo quality, implantation, and the rate of miscarriage is supported by the preliminary data (18), but it remains controversial. Here we detected no effect of metformin on rates of fertilization, implantation, and miscarriage, or on the quality of the zygote/cleaved embryo, transferred embryos (19) or on pregnancy, multiple pregnancy, OHSS, or live-birth rates (3).…”

In-vitro maturation of human oocytes: before or after vitrification?

“…The development of an effective cryopreservation program for immature oocytes may have a major impact on in vitro fertilization (IVF) clinical practice, especially to preserve the fertility of women who will be treated with cytotoxic drugs [1,2] or for women with polycystic ovarian syndrome (PCOS) at risk of ovarian hyper-stimulation syndrome (OHSS) [3][4][5]. Moreover, for cancer patients, transplantation of cryopreserved ovarian tissue is not always conceivable because of the risk of retransmission of the disease due to the presence of neoplasic cells in the tissue.…”